Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice

The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...

Descrición completa

Gardado en:
Detalles Bibliográficos
Autor Principal: I. V. Kolyadina
Formato: Artigo
Idioma:Russo
Publicado: ABV-press 2021-09-01
Series:Opuholi Ženskoj Reproduktivnoj Sistemy
Assuntos:
combined endocrine therapy
inhibitors cdk4/6
ribociclib
monaleesa-2
monaleesa-3
monaleesa-7
visceral crisis
Acceso en liña:https://ojrs.abvpress.ru/ojrs/article/view/845
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares